The ZBTB10 antibody is a tool used to detect ZBTB10 (Zinc Finger and BTB Domain-Containing Protein 10), a transcription factor belonging to the BTB/POZ-zinc finger family. ZBTB10 is implicated in transcriptional repression and regulation of cellular processes, including cell proliferation, differentiation, and apoptosis. It shares structural homology with other ZBTB proteins, featuring an N-terminal BTB domain for protein interactions and C-terminal zinc fingers for DNA binding. Research suggests ZBTB10 may act as a tumor suppressor by inhibiting oncogenic pathways, such as those driven by Sp1 transcription factor, which is often overactive in cancers. Studies have linked ZBTB10 to the modulation of genes involved in cell cycle control and stress responses, though its precise mechanisms remain under investigation.
The ZBTB10 antibody is primarily employed in molecular and cellular biology research to study protein expression, localization, and function via techniques like Western blotting, immunohistochemistry, and immunofluorescence. It has been utilized in cancer research to explore ZBTB10's role in tumorigenesis, metastasis, and therapeutic resistance. Dysregulation of ZBTB10 has been observed in malignancies such as breast, liver, and colorectal cancers, highlighting its potential as a biomarker or therapeutic target. However, challenges persist in fully elucidating its interaction networks and regulatory pathways. Ongoing research aims to clarify its contributions to epigenetic regulation and disease progression, underscoring the antibody's utility in advancing mechanistic and translational studies.